VAXART INC. - COMMON STOCK

Vaxart Announces First Subject Enrolled in Phase 1b Norovirus Boosting Regimen Study

04 May 2021 08:00:01 By Nasdaq GlobeNewswire

New Data from Vaxart Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity against Other Coronaviruses

03 May 2021 17:06:20 By Nasdaq GlobeNewswire

Vaxart Reports First Quarter 2021 Financial Results and Provides Business Update

03 May 2021 08:00:02 By Nasdaq GlobeNewswire

Vaxart to Present at the World Vaccine Congress Washington 2021

29 Apr 2021 08:00:01 By Nasdaq GlobeNewswire

Vaxart to Host a Key Opinion Leader Webinar on the Importance of T-Cell Responses for COVID-19 Vaccines

26 Apr 2021 08:00:01 By Nasdaq GlobeNewswire

Vaxart Appoints David Wheadon, M.D., to its Board of Directors

23 Apr 2021 08:00:00 By Nasdaq GlobeNewswire

Poll: Oral Covid-19 Vaccine Pill Offers a Way to Overcome Vaccine Resistance of Millions of Americans

22 Apr 2021 08:00:03 By Nasdaq GlobeNewswire

Vaxart to Present at the H.C. Wainwright Global Life Sciences Conference

04 Mar 2021 16:01:00 By Nasdaq GlobeNewswire

Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

25 Feb 2021 16:01:01 By Nasdaq GlobeNewswire

Vaxart to Provide 2021 Business Outlook on Tuesday, March 2, 2021

24 Feb 2021 16:01:00 By Nasdaq GlobeNewswire

Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

03 Feb 2021 08:30:00 By Nasdaq GlobeNewswire

Vaxart Announces Publication of a Peer-reviewed Journal Article Showing the Potential Clinical and Economic Value of a Norovirus Vaccine

27 Jan 2021 08:30:00 By Nasdaq GlobeNewswire

Vaxart Announces Additional Preclinical COVID-19 Oral Vaccine Data and Publication

26 Jan 2021 08:30:01 By Nasdaq GlobeNewswire